A regional frequency is not automatically benign evidence

FranceGenRef may become relevant to rare disease interpretation if it provides regional allele frequencies that are missing from larger reference datasets. The classification question is narrower than whether a variant appears in the panel. Population frequency must be evaluated against disease prevalence, inheritance mode, penetrance, allelic heterogeneity, and the panel's sampling structure. Reference datasets may also contain affected individuals or related participants.

Family evidence remains separate. A frequency observation can weaken a proposed highly penetrant rare disease mechanism, but it does not resolve phase, phenotype concordance, de novo status, or segregation within the pedigree. Regional absence is also weak when coverage or sample count leaves the allele poorly observed.

For candidate variants, will the resource report allele count, callable chromosome count, relatedness filtering, regional sampling, age information, and local ancestry at the locus?